Finn Patrick John has recently filed a Form 144, which reports his intention to propose the sale of securities. This filing, dated October 23, 2026, is significant as it may indicate a shift in his ownership stake.
Finn Patrick John is associated with Twist Bioscience Corp, which operates in the biological products sector. The company is based in South San Francisco, California, and is known for its innovative approaches in the life sciences field.
The filing states, "Report of proposed sale of securities," although specific details regarding the number of securities or the timing of the sale were not disclosed. This lack of detail leaves some uncertainty regarding the implications of the proposed sale.
This move may affect various stakeholders, including investors and competitors in the biological products industry. The filing indicates ongoing activity in the market, which could influence investor sentiment and competitive dynamics.
The filing does not say what happens next.
Company Information
Twist Bioscience Corp, the company associated with Finn Patrick John, has a Central Index Key (CIK) of 0001581280 and is incorporated in Delaware. The company's fiscal year ends on September 30, and it operates under the Standard Industrial Code (SIC) 2836, which pertains to Biological Products, excluding Diagnostic Substances.
Filing Details
The Form 144 was accepted by the SEC on the same day it was filed, October 23, 2026, at 15:15:05. This indicates a prompt processing of the filing, which may reflect the urgency or importance of the proposed sale.
Contact Information
Finn Patrick John's mailing address is listed as C/O Twist Bioscience Corporation, located at 455 Mission Bay Boulevard South, San Francisco, CA 94158. The business address for Twist Bioscience is also the same, indicating a close operational relationship.
"Report of proposed sale of securities"
While the filing does not specify the number of securities involved in the proposed sale, it highlights an active engagement in the market by Finn Patrick John, which could have broader implications for the company's stock and investor relations.